Therapy-related acute myeloid leukemia with 24-month latency after CD19 CAR-T cell therapy in relapsed/refractory diffuse large B-cell lymphoma: a case report - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Acute Myeloid Leukemia Induced by Therapy with a 24-Month Latency Following CD19 CAR-T Cell Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Case Study

  • By

  • Manqi Su

  • Chentong Huang

  • Zhanna Zhang

  • Xiaoxia Wang

  • Panruo Jiang

  • Yiran Chen

  • Gongqiang Wu

  • August 14, 2026

Share

Original Source(s)

Therapy-related acute myeloid leukemia with 24-month latency after CD19 CAR-T cell therapy in relapsed/refractory diffuse large B-cell lymphoma: a case report

  • by Manqi Su, Chentong Huang, Zhanna Zhang, Xiaoxia Wang, Panruo Jiang, Yiran Chen, Gongqiang Wu

  • August 14, 2026

Related Content

Correction: Serial ctDNA dynamics predict clinical outcomes in metastatic and locally advanced PDAC: a systematic review

National Cancer Institute–Supported Obesity and Cancer Research, 2015-2022

Correction: Review and analysis of clinical trials of selective RET inhibitors for the treatment of thyroid cancer